The layoffs come as Moderna’s cash position has raised worries on Wall Street that the company may need to raise new capital.

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The biotech company’s revenue halved in 2024, and it continues to face uncertainty in the vaccine market. Biotech giant ...

CEO Stephane Bancel announced on Thursday that the company plans to cut nearly 10% of its global workforce by the end of 2025 ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

As of March 31, Moderna had $5.97 billion in cash and short-term investments, with total debt of $745 million. But the ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Massachusetts-based Moderna announced Thursday that it plans to slash the size of its global workforce by about 10% in the coming months as COVID vaccine sales continue to decline. In a memo that was ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...